| pubmed-article:15840684 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15840684 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15840684 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:15840684 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:15840684 | lifeskim:mentions | umls-concept:C0019004 | lld:lifeskim |
| pubmed-article:15840684 | lifeskim:mentions | umls-concept:C1524112 | lld:lifeskim |
| pubmed-article:15840684 | lifeskim:mentions | umls-concept:C0449259 | lld:lifeskim |
| pubmed-article:15840684 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:15840684 | pubmed:dateCreated | 2005-5-16 | lld:pubmed |
| pubmed-article:15840684 | pubmed:abstractText | Chemotherapy is not given routinely to patients with malignancies receiving chronic haemodialysis because evidence of a clear benefit is still lacking and severe side effects are feared. The aim of our retrospective study was to analyse the methods of dose adjustment and the clinical course of chronic haemodialysis patients with malignancies treated by chemotherapy. | lld:pubmed |
| pubmed-article:15840684 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15840684 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15840684 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15840684 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15840684 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15840684 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:15840684 | pubmed:issn | 0931-0509 | lld:pubmed |
| pubmed-article:15840684 | pubmed:author | pubmed-author:KargesWolfram... | lld:pubmed |
| pubmed-article:15840684 | pubmed:author | pubmed-author:SeufferleinTh... | lld:pubmed |
| pubmed-article:15840684 | pubmed:author | pubmed-author:KellerFrieder... | lld:pubmed |
| pubmed-article:15840684 | pubmed:author | pubmed-author:CzockDavidD | lld:pubmed |
| pubmed-article:15840684 | pubmed:author | pubmed-author:RascheFranz... | lld:pubmed |
| pubmed-article:15840684 | pubmed:author | pubmed-author:GriesshammerM... | lld:pubmed |
| pubmed-article:15840684 | pubmed:author | pubmed-author:BoeslerBenjam... | lld:pubmed |
| pubmed-article:15840684 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15840684 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:15840684 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15840684 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15840684 | pubmed:pagination | 1187-91 | lld:pubmed |
| pubmed-article:15840684 | pubmed:meshHeading | pubmed-meshheading:15840684... | lld:pubmed |
| pubmed-article:15840684 | pubmed:meshHeading | pubmed-meshheading:15840684... | lld:pubmed |
| pubmed-article:15840684 | pubmed:meshHeading | pubmed-meshheading:15840684... | lld:pubmed |
| pubmed-article:15840684 | pubmed:meshHeading | pubmed-meshheading:15840684... | lld:pubmed |
| pubmed-article:15840684 | pubmed:meshHeading | pubmed-meshheading:15840684... | lld:pubmed |
| pubmed-article:15840684 | pubmed:meshHeading | pubmed-meshheading:15840684... | lld:pubmed |
| pubmed-article:15840684 | pubmed:meshHeading | pubmed-meshheading:15840684... | lld:pubmed |
| pubmed-article:15840684 | pubmed:meshHeading | pubmed-meshheading:15840684... | lld:pubmed |
| pubmed-article:15840684 | pubmed:meshHeading | pubmed-meshheading:15840684... | lld:pubmed |
| pubmed-article:15840684 | pubmed:meshHeading | pubmed-meshheading:15840684... | lld:pubmed |
| pubmed-article:15840684 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15840684 | pubmed:articleTitle | Clinical course of haemodialysis patients with malignancies and dose-adjusted chemotherapy. | lld:pubmed |
| pubmed-article:15840684 | pubmed:affiliation | Division of Nephrology, University Hospital Ulm, Germany. | lld:pubmed |
| pubmed-article:15840684 | pubmed:publicationType | Journal Article | lld:pubmed |
